Aldeyra Therapeutics Files 8-K Report

Ticker: ALDX · Form: 8-K · Filed: Jul 17, 2025 · CIK: 1341235

Aldeyra Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAldeyra Therapeutics, INC. (ALDX)
Form Type8-K
Filed DateJul 17, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-filing, pharmaceutical

TL;DR

Aldeyra Therapeutics filed an 8-K on 7/17/25. Standard corporate update.

AI Summary

On July 17, 2025, Aldeyra Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorporated in Delaware with its principal executive offices located in Lexington, MA. The report does not contain specific financial details or event descriptions beyond its filing status.

Why It Matters

This 8-K filing serves as a notification to the SEC and the public about significant corporate events or financial updates for Aldeyra Therapeutics, Inc.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not disclose any new material risks or adverse information.

Key Players & Entities

FAQ

What is the exact date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is July 17, 2025.

What is the company's full legal name as specified in its charter?

The company's full legal name is Aldeyra Therapeutics, Inc.

In which state was Aldeyra Therapeutics, Inc. incorporated?

Aldeyra Therapeutics, Inc. was incorporated in Delaware.

What is the address of Aldeyra Therapeutics, Inc.'s principal executive offices?

The address of the principal executive offices is 131 Hartwell Avenue, Suite 320, Lexington, MA 02421.

What is the Standard Industrial Classification (SIC) code for Aldeyra Therapeutics, Inc.?

The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 17, 2025 regarding Aldeyra Therapeutics, Inc. (ALDX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing